Aeterna Zentaris to Participate at the Virtual Investor 2022 CEO Spotlight
April 12, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Live moderated video webcast fireside chat with Dr. Klaus Paulini, CEO and Giuliano La Fratta, CFO of Aeterna Zentaris, on Thursday, April 14th at 10:00 AM ET TORONTO, ONTARIO, April 12, 2022 ...
Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity
April 11, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder ("NMOSD"), an orphan indication with strong unmet medical need ...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Outlook
March 29, 2022 08:00 ET
|
Aeterna Zentaris Inc
– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 ...
Aeterna Zentaris Announces Expansion of Research Program with Julius-Maximilians-University Wuerzburg Aiming to Accelerate Development of Vaccine Programs
March 10, 2022 07:05 ET
|
Aeterna Zentaris Inc
– Research agreement expanded for development of human 3D intestinal tissue models to study Salmonella enterica pathogenesis TORONTO, ONTARIO, March 10, 2022 (GLOBE NEWSWIRE) -- Aeterna...
Aeterna Zentaris to Present at the 2022 BIO CEO & Investor Conference
February 07, 2022 08:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
January 26, 2022 16:05 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Provides Business Outlook and Outlines Pipeline Priorities
January 26, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Company advancing diversified portfolio focused on areas of significant unmet medical need– Supported by solid financial position with cash to fund operations beyond 2023 TORONTO,...
Aeterna Zentaris to Present at the Virtual Investor 2022 Top Picks Conference
January 20, 2022 08:05 ET
|
Aeterna Zentaris Inc
– Live video webcast presentation on Wednesday, January 26th at 9:00 AM ET CHARLESTON, S.C., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the...
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
January 05, 2022 08:36 ET
|
Aeterna Zentaris Inc
CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and...
Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
December 23, 2021 16:05 ET
|
Aeterna Zentaris Inc
– Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors TORONTO, ONTARIO, Dec. 23, 2021 (GLOBE NEWSWIRE) --...